CONTACT US
Home > Inhibitors/Agonists>HCV Protease> > Danoprevir
Danoprevir

Danoprevir

  • CAT Number: I005105
  • CAS Number: 850876-88-9
  • Molecular Formula: C35H46FN5O9S
  • Molecular Weight: 731.83
  • Purity: ≥95%
Inquiry Now

Danoprevir (Cat.No:I005105) is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor. It works by blocking viral replication and inhibiting the enzyme necessary for viral replication. Danoprevir, in combination with other antiviral agents, has shown promising results in the treatment of chronic hepatitis C. 

Catalog Number I005105
CAS Number 850876-88-9
Molecular Formula

C35H46FN5O9S

Purity 95%
Target HCV Protease
Solubility DMSO:≥144 mg/mL;Water:1 mg/mL; Ethanol:≥144 mg/mL ;
Storage 3 years -20℃powder
IC50 0.2-3.5 nM
IUPAC Name [(1S,4R,6S,7Z,14S,18R)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate
InChI InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1
InChIKey ZVTDLPBHTSMEJZ-JSZLBQEHSA-N
SMILES CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
Reference

</br>1:Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H, Brennan BJ, Zhou J, Le Pogam S, Najera I, Thommes JA, Hill G.J Gastroenterol Hepatol. 2016 Oct;31(10):1757-1765. doi: 10.1111/jgh.13374. PMID: 26992248 </br>2:Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T.Mol Biosyst. 2016 Nov 15;12(12):3666-3673. PMID: 27731877 </br>3:Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV – some considerations. Srinivas NR.Antivir Ther. 2016;21(7):647-648. doi: 10.3851/IMP3046. Epub 2016 Apr 1. No abstract available. PMID: 27550927 </br>4:Reply to: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV – some considerations. Canini L, Guedj J, Perelson AS.Antivir Ther. 2016;21(7):648-649. doi: 10.3851/IMP3045. Epub 2016 Apr 1. No abstract available. PMID: 27550924 </br>5:Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S, Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J.Hepatol Int. 2016 May;10(3):478-87. doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17. PMID: 26886127 </br>6:Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. Canini L, Guedj J, Chatterjee A, Lemenuel-Diot A, Smith PF, Perelson AS.Antivir Ther. 2016;21(4):297-306. doi: 10.3851/IMP3006. Epub 2015 Nov 10. PMID: 26555159 Free PMC Article</br>7:Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. Song ZZ.J Hepatol. 2015 Sep;63(3):769-70. doi: 10.1016/j.jhep.2015.03.042. Epub 2015 Jul 2. No abstract available. PMID: 26142179 </br>8:Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. Brennan BJ, Poirier A, Moreira S, Morcos PN, Goelzer P, Portmann R, Asthappan J, Funk C, Smith PF.Clin Pharmacokinet. 2015 May;54(5):537-49. doi: 10.1007/s40262-014-0222-6. PMID: 25488594 </br>9:A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Canini L, Chatterjee A, Guedj J, Lemenuel-Diot A, Brennan B, Smith PF, Perelson AS.Antivir Ther. 2015;20(5):469-77. doi: 10.3851/IMP2879. Epub 2014 Oct 16. PMID: 25321394 Free PMC Article</br>10:Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES.J Hepatol. 2015 Feb;62(2):294-302. doi: 10.1016/j.jhep.2014.09.013. Epub 2014 Sep 18. PMID: 25239078

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!